Welcome to COMPLEMENTO Program Website, “Biology and Physiopathology of the Complement System”. It is an I+D Activity Program funding by the Regional Government of Madrid and comprises 7 research groups. It is coordinated by Dr. Santiago Rodríguez de Córdoba from the Biological Research Centre in the Spanisch National Reseach Council (CSIC). COMPLEMENTO Program develops a multidisciplinary and translational approach to study the physiopathology of the complement system.
Complement is a major component of innate immunity with crucial roles in bacterial killing, apoptotic cell clearance, immune complex handling and modulation of adaptive immune responses.
The complement cascade is triggered by three activation pathways, the classical pathway (CP), the lectin pathway (LP) and the alternate pathway (AP).
Complement is implicated in a long list of disease. In some cases, including rheumatoid arthritis, systemic lupus erythematosus, glomerulonephritis, multiple sclerosis, ischaemia/reperfusion injury. In some of these pathologies, complement acts to sustain the “vicious cycle” of inflammation and perpetuate tissue damage. In others, complement is the cause of the disease as dense deposit disease, atypical hemolytic uremic syndrome and age-related macular degeneration. Members of the COMPLEMENTO Program have established that these diseases are each associated with rare mutations or common polymorphisms in the components and regulator of the alternative pathway of the complement system.
The COMPLEMENTO Program is clearly multidisciplinary and generates an efficient and competitive research structure to act against specific problems of the complement physiopathology. Studying aspects related to the functional and structural characterization on genetic variants, the analysis of the structure and the molecular mechanisms responsible of the activation and regulation of the complement system, are contributing to understand how complement functions are altered in pathological conditions and identify targets in order to develop drugs.
Reach this knowledge is a difficult work that demand a multidisciplinary approach and an effective communication between clinical and basic investigation. The developed activity plays an important translational role as well as a great transfer knowledge to the industry.